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Aims Propofol is the most widely used intravenous anesthetic medication. It is necessary to assess the doses of the medication to determine proper anesthetic depth and to prevent its side-effects. The aim of this study was to compare 1 and 2.5mg/Kg doses of propofol in hemodynamic changes, myoclonus degree, and bi-spectral index (BIS) monitoring level in patients under anesthetic induction.
Materials & Methods In the two-blind random clinical trial study, 92 patients being candidate for surgery wit general anesthesia induction were studied in Shahr-e Kord Kashani Center in 2013. The subjects, selected via simple sampling method, were randomly divided into two groups. 
The first and the second groups were received 1 and 2.5mg/kg doses of propofol, respectively. Hemodynamic, myoclonus, and BIS indices were measured at four different times in the groups. Data was analyzed by SPSS 17 using independent T and Chi-square tests, as well as repeated ANOVA and Fisher’s test.
Findings There was no significant difference between the groups in the hemodynamic variables such as systolic and diastolic blood pressure, mean arterial blood pressure, pulse rate, and BIS (p>0.05). In addition, the change rates of the variables were the same. 
Nevertheless, there was a significant difference between the groups in the pulse change rate 
(p=0.032). There was no significant difference between the groups in myoclonus (p>0.05).
Conclusion The hemodynamic changes and the changes in myoclonus degree and BIS are the same in 1 and 2.5mg/kg doses of propofol in the patients undergoing anesthetic induction.
A B S T R A C TA R T I C L E    I N F O
Article TypeOriginal Research
AuthorsShabanian Gh.1 PhD,
Rafie M.1 MD,Heidari-Soureshjani S.2 MSc,Shabanian A.R.3 MSc,Shabanian M.R.* MSc
How to cite this article
Shabanian Gh, Rafie M, Heidari-Soureshjani S, Shabanian A.R, Shabanian M.R. Comparison ofHemodynamic Variations, Bispectral Index and Myoclonus Score of Propofol Dosage in Anesthesia Induced Patients.Quarterly of the Horizon of MedicalSciences. 2016;22(3):171-176.
Copyright© 2016 ASP Ins. This open-access article is published under the terms of the Creative Commons Attribution-NonCommercial 
4.0 International License which permits Share (copy and redistribute the material in any medium or format) and Adapt (remix, transform, 
and build upon the material) under the Attribution-NonCommercial terms.
 !	)- .
/0 !"1 &  
  	 




  BIS  











  	     
	
  MD  
   
 
  	     
   MSc  
! "#$%"  &'()  
 
  	   
 	 MSc  
 *  






 MSc  
     
+, 




  	     
    !" #
   	  $ %	$ &
 . ' () *" $ +,-/ &#0 	1 &2	 /$ 
3	 4  564  56 /4 78
   564  56 
9:4 &; 13	!/  <0 BIS )=	  (?@ AB 
(! C
  .   

   	 : % %	$) &#0 	 %D
   
    ! %!"    %E; F!" 	: 
	) G   %: H 5I:.  	! (& &:!: J  6
 J KLM: () &   & %D
 7N: O2
 J6 . J6 
 $3	 4  564  56  J65  $/4  564  56
  : 	 AB  /  9:4 &; 13	!/
 <0BIS   . JI :)  7?M ($ PJ F4C
  /
& 3! 5: G SPSS 17 ($) $ J?M    /T  QI 1FM2
6 5I: , ($)  7/, R
  S:	 G:) 1.  
 :	  13M2 (B , T: 3	!/ /8M
 AB  UV: (' 1%:	 WM (B , 13M	BIS  
 ) -XMB J6   Y4ML ($ P#  M: 
)	/	p>(: Z!/ . 78
  1 (2R	 G: /8M 	 : 
#
 78
 ('  UV:  J6 7?
 #  (,:  
)	/	=p(. # 7?
 G: 9:4 $ T: $  J6   
) ,: J/,	/	p>(.  
 :  13	!/ 78
 1  C
 (! 
 <0  9:4 &;BIS 3	 $   4   564  56
/4  . (2R	  564  56  
!  :"-!'	./ 0	(	 $ 12 3 	
 
:(& 4&$ //  
:56 4&$ //  
*
 :0	78! '8	shabanian.mohammadreza@gmail.com  
  
,  
  	 
         
  !"  #$ #%" &'()*     +,*
 !""* -.* /0(* * 10( [1, 2].   $,23
  1,4 5    !" *36 #$  $ 
1  -36 7  89  /*,"*  :"; <) * 10(
 =* $>[3, 4] $? @ #$   
  .
B'= 1$9C < D <4 1  10( D=6 $	* 
$4,  * = )*      /E    $>
* < [5-7] .  9   ?*  F4$* 
G  
 H@ * , F3$[8] . #%"  
 $,23
 #$   I$  
J(* #$ K;  4L F,6
M  $)B * 10( )*  N$,O$  [6] J .
  ,, G    ,9 = F3$ 
  
/* * < 4$" (. F*  %  .*  $,23 .
-9 #$   -36  : 1  F3$ D
  4$" PJ* N4  " (# Q.G -36  :  $G
 9 3$ $JR  ($ R[7, 9] .  
ST9  JU* N 5  
 &'()*  .*
#$   < Q  0$5 V9(BIS)  F"
 1  */'$*  >'$  > * (# 

 1) WU  F$ BIS 3* 1    -$"(, X*
[10]<  10( . BIS  FY     #$ $G
*    K 3$   B,* #$ Z36 ">Y F
  #$  I,*   !$(" [11-16] .  
	  [6  
  	%"\  !" 
DF$(, /G (9"   " Q"'$* R6 . 
Q"'$*  * JU* N 5 
 ] M4> 1 
D   L  	"Y      
 #$  D  ^R* $3 1_ $  
* ,[17]. * (0>    K
  ! H6
@U #$D `    : N$*,3 
	%"\D  $  #$ $G /59 Y R6
* #$ $G Z$36 H6   $,23 .  ($ F
.0, B'= F$  #$  3$ a*  !,* (G  1
* [18] .   (# F     Z36 FY
 Y R6   N$*,3 (9" /$$b  #$
 D13" $>'L #$ $G $  #$ $G /59
 VT)(* $,23  GL $G 3$  (# c
    	
 		 
BIS 	   !"	 " #$%&% '& ()*+	
 ," &   
Q Horizon Med Sci                                          Vol. 22, Iss. 3, Sum 2016 
 #$   /+"  #$  $G #$ K
*  .,  
d JU* D .*  N '$*  >'$  > 
/'$* /$$b  
 >'$  >  L DN$*,3
Q"'$*  WU BIS  F3$ @  . #$  
  
-     
 ,$ *Y JU*  T   
  
 GL -36 "  Y 4*   # " e
1 JL*  D" !".  3$ F, $$   	  

  Qf    NASA  FTT)(* 3!")  (	*Y 
"  > = *36 #$   GL -36 @,(. 
$J*  89  JU* -*  F23 *  R 6
 1* DJU*   <$ -=$i R6 ">  J ,$
  ($ Qfj D
 Z4    NASA 3$  D
$.G  F$	"(, D   3$?     10( 
" #$ Z36 F DJU* !"  . 
  3$
 "3" 1$  1 k)(" FY $>     T /E
 1> 1>  " K$. 0"
   N '$*   >
 >'$  1>   /'$*  >'$  > @ 

= #$  ,(>[19] .  
 Y4,* $F3  G$ #$  "$Q( . 10(  .
  #$  IT" D- >*Y Dl,($"*  : DF3$
 1%( "$ $BIS  B?  I'= FR  F9  
(, 
 . ^ #"Y
(,$ Kf6 $   : 'Ef K 
#$ Z36 <  Z4 3$.  -$"(, 1>    
>'$  >	$* $" I.G   1  F$	* *
 10(> = -    Y 1,, F4$* /'$*  >
 >'$   -$#.  "fm6 ',10( F$( .   
 GL )  3$ (  :   <$ $= 
#$ N D  $=  J 'Ef  #$   J $=
DN$( F9  DN$(.$ F9  DF$(,   J
nB" FR    F9 #$ F(, c " c(*
1"  Q"'$* $,23 . $>N    J $=
<"	 L Q    #$[20]   B?$ L .
 Q$* N <"	 F" 0E FY      6 1,
J$B5$i G ">  !D  N   J$B5$i G ,J*
"   N      "   <$  J$B5$i G ,J*
 ,  "[17]   : $ WU $,23 .
D#$  1%( cBIS  B?  1$!,  C -= .
   -$1>  F(, DJU* F  (" ^f5 ,
* Z4 #$ VT)(* c     E  .
  F3$ N '$*  >'$  > %, 
 F$(,
*  "
(,$    K   '$*  >'$  > 
  #$ I,* Z36 !  3$  10( F$(,
* dXG JU*  .  
  F3$  o* /6f5 Np  .$ -*Np .$ 
$b(* Np  N$>*  $b(* <!, .$  
N$*,3 D WU  Q"'$*BIS 3L Y . f6  1
D$%"$* B@* d@" $J*   "    DB."
 F*Y  , $%"$* +"  1> T    D-(.*
 QfASA  D X!* F*Y  N$>* $b(*  
V9 .*   N$*,3  WU BIS   1>  
 F*YT   -(.* F*  $b(*  .*  &'()* 
 $,23 . 10( /* 	  :" 4$"Y F*Y 
1>   Q"'$* L    * $ F*Y
1 -$'@ .> = 10(   N3 " 4 SPSS 17 
 !".  
  
.#   
 
 3$ j  JU* j "3"  0" ) 1>   
0" ( -$ dT"  q3D  JU* 89 "   #" 
/6f5 o*    3$* 4!  -$'@ #" = 
> . 
 1>  F3$  $%"$*/
±/    

  1>/
±/  . 
+"  1>  $  
,J* df(9  F.3 +"   1>   " 1* 
) "/=p $b(*  +"  1>  $ $,23 .(
,J* df(9 4$" N$>*  
L) " L  .(  
  
 # ( (; ,& < =2 ) ?8  @A! ( BC	$
 &. -(	! D/E<!- C) 0  !  (0	(	 	  
 C)   	/
! (0	(	 	    
"	$%
  
 # 	&  
) (+  
 '( 	&  
)  (+  
 )*
+,
 -(  
./,  
! )	/ (




  )/ (  
0  
C <.0;  )/ (  )/ (  









  )	/	 (
  
/  
 GH )/ (

  )	/ (
  
  
 DN$( DN$(.$ F9  $+" N$*,3 $b(*
) F* #p  nB" FR  " c(* F9   $=
 !	)- .
/0 !"1 &  
  	 
                                                
 D#$   J $= N D#$   -B=  J $=
 df(9 1>   (F$(,  J 'Ef  #$  
,J* *Y " ) ,(/p>( V9 ST9  .BIS  D
 WU ($ 1>  BIS     #$  -B= $=
 $,23 . #$  J $= N  o* FY (3 
" /$$b V9   F9 DN$(.$ DN$(  
F9 c(* "  Z36 #$   1>  df(9
,J*  " 1  F" 1, 	'36 F.	    

   V9  * D " J /$$b FR  nB"
$  1> /0 ,J*  F"  
L) (.  
ST9   " L  DQ"'$* 1> 
  0" 
)/Q"'j$* (% D0E  0" )/Q"'j$* (% s   
) 0"/Q"'j$* (%  .,(  1>  4$"   0"
)/	(% Q"'j$* D0E  0" )/	Q"'j$* (% s    0"
)/Q"'j$* (%   ,(  +" L Q"'$*   
1> ,J* /0 1*   ")	/=p(.  
  
 #(  IA;  -!'	./ )/E<! )&!J K! L8"!BIS - C) 0  K !  C)    (0	(	 	  	/
!  	  
!C & (0	(	 M<N! D/  
3
,4(" -"	$%
 # 	& '( 	& +,
 )* 	& ( 05 -( +,
 )* 
6 05 -( "  
 37%/ 8 9!) (	O <!  
		























 37%4( 8 9!) (	O <!  
		








  /±//±//  
 4	 ;%
 8 9!) (	O <!  
		


















<L"P & $)(  
		




±	/ 	/±	/ /  
L,(H ;	<'	  /±/ /±	/ /  
	PL"C 	
  	/±/ 	/	±	/ /  
=8BIS  
		
 C =?P L"P  	/





 /  
L,(H ;	<'	  /±	/	 /±/ 	/  
	PL"C 	
  	/±		/ 
/±
/ /  
  
/(%  
N$(.$ F9  /$$b  L  N$(   
F*  JU* * *0> FD    : 1>   
 G  #$ tF9   N$(  N$(.$ 
DK  	%"\  : 'Ef *  N@ ! -$
Du"  <4 G  F9   /*   
 $=d5  #$ Z36 <4  FY  :  N@ F
 <  (>  G  	%"\.  /"" 
  
vET9 4 F9  < N$(  N$(.$ 
 1> 
  1>  ($D   	%"\ !"  :  5
. 1 
 1>  F9   ($ <4  : $,23
B@*    F* #p $%"$* 1>D   $%"$* /$$b
1> F9   1>  ($ 3 
D  +"  1>  $ *
F9  /$$b N$(.$ ,J* /0 " L    
 ".	 " 1> ,(.   
    	
 		 
BIS 	   !"	 " #$%&% '& ()*+	
 ," &  	 
Q Horizon Med Sci                                          Vol. 22, Iss. 3, Sum 2016 
 JU*   F9  <4 F	3   
B"  X>
J* 1>  ,  M4> . 1>  N '$*  >'$  >
) <4 ($/(%   11>    /'$*   >
 >'$)/(%   '$*  >'$  > 1 F9  <4
* M4> JU*  ."  1>  , '$*  >'$  >
 1>  B."N '$*  >  >'$    
(, (#
 F9[10] ( *  B" * JU* .  JU*  $,23
	
     1 F$ F	3 /'$*   >
  >'$/'$* ,J* /0 
 >'$  >   
  (" nB" FR  N$(  N$(.$ F9  *
 =  -$"(,  \$*   1" F3 
 ?* 
05  N* 
_"\[21] . JU*  *  .*
 " 4$" " c(* F9  /$$b ST9  1>
F" ".	 . 
    M4>1  "   /0
/*   F\.>4  #$  $G 
 Z4 F*
nB" FRD N$( F9 D  F9   N$(.$
" c(*,J* *Y /0  3" !  ,[22] .  
 JU*  RG /0 1>   nB" FR V9 /$$b
,J*  F" D   
 1>  nB" FR F"  5
F*    1>  ($ +" *   *Y  df9 
(  JU*  * JU*   F	3  FR <4
 1>   nB" DN/  '$*  >'$  > F.	
 M4>[10] ./0   ,J* RG JU*    F( 
   F,6 ">    
 1> N '$*   >
 >'$* 10( 
 D ` nB" FR    
B"
@ 	%"\ N 3" #* 9  1>  *   1
` #*  1f6  DnB"   !  
 /?
 1 #* ($ 	D 10(     p 
* * 	 !  !,* 9  1  .  
ST9   <BIS DU  1>   W   
 GL -36  (.( =,  B,* #$ Z36  .
 JU*  F	3    1  6 (#BIS  F* 
 6 #$  D  3R #$  Z36   Fp
  #$ $G  " F9  	,   -9 X>
 (3(  $$b D3f6  1" 1 4$" 3$ $ 
[23] . * M4> 9 JU*   <  10( ,BIS 
 6) I,* #$ Z36 $*   < IL* (
) $%3p(%  
  3f +'i  Z4 *
* [17] .
 U*  F	3 * C 9 J  < ,,
BIS K  	"Y  <$  #$  dT* F4$* F
K  !,*  ?*   J Y  $ ,$ Kf6 F
 1 -36[11] .  
 Q"'$*  * JU*   
 1>  #$  
B"
/%   1>  / M4> %D    5
   N 	  Q"'$* ( ) 1>  ($ 
 1> 
 ,J* /0   D  .B"  JU*   F	3 
N   1 F" '$*  >'$  > 
TG  
  $G (G .$"   X>D  1> */  
'$*  >'$  >,(. I,* +"  [10]  (  
 .B" .3 RG JU*  -EG P(" (   % JU*
4$" F"   B." F3$   Q"'$* \  1,
 ,*   1C *Y  !,* \ *Y  !  
$R B*   
 $" *  F4$*  _" $?  ,
 Q"'$*   #$ k'U* WU  F$[17].  
 w$ B3BIS   JU*      ** 
@* '3L  . JU* w P("  L     1*Y
 DRG JU*,* Z36 
TG   $>'L  #$ I
* (9" /$$b  F $* 5 Y  4$*   
 * . 10(D C  \ >   pN '$*   >
 >'$ T(= x@   E  (3  [6 
 * #,$ * D 9 13    I,*  k)("
F=+"  3$ ,$ c V$)   VT)(* N4





 L DN$*,3 /$$b D#$  @ F3$ 
 WU  Q"'$*BIS N    '$*   >'$  >
/'$*   > . F.	 
 >'$  
  
: 	 
  (@* "J* * 3G  '$ 
  F3$ Dj# q4 '6 1%" _  ".j *3
 j ( q3 <_  -$3q  L  @"  q D"
* "=  .   
:   1%  RG JU*IRCT  *Y  
,$ IRCT2015030218099N3     1$ B?
 1%" 	4 7f9 ($3 c FY =f9 !* $,23
) # 	4 '6 7f9 	( . 1 X9  
 : w* . 1" F$ F>,." c  
:  F -EG *   *36 q4 *"  13
  # 	4 '6 1%"     * 3G
 	4 '6 1%" ,  /$@ "J* c <_




/0 !"1 &  
  	 
                                                
2% 
1- Karen T, Schlager GW, Bendix I, Sifringer M, Herrmann 
R, Pantazis C, et al. Effect of propofol in the immature rat 
brain on short- and long-term neurodevelopmental 
outcome. PLoS ONE. 2013;8(5):e64480. 
2- Anghelescu DL, Hamilton H, Faughnan LG, Johnson L-
M, Baker JN. Pediatric palliative sedation therapy with 
propofol: Recommendations based on experience in 
children with terminal cancer. J Palliat Med.  
2012;15(10):1082-90. 
3- Hong JY, Kang IS, Koong MK, Yoon HJ, Jee YS, Park JW, 
et al. Preoperative anxiety and propofol requirement in 
conscious sedation for ovum retrieval. J Korean Med Sci. 
2003;18(6):863-8. 
4- Rahman NH, Hashim A. Is it safe to use propofol in the 
emergency department? A randomized controlled trial to 
compare propofol and midazolam. Int J Emerg Med. 
2010;3(2):105-13. 
5- Horiuchi A, Nakayama Y, Kajiyama M, Kato N, 
Kamijima T, Ichise Y, et al. Safety and effectiveness of 
propofol sedation during and after outpatient 
colonoscopy. World J Gastroenterol. 2012;18(26):3420-
5. 
6- VanNatta ME, Rex DK. Propofol alone titrated to deep 
sedation versus propofol in combination with opioids 
and/or benzodiazepines and titrated to moderate 
sedation for colonoscopy. Am J Gastroenterol 
2006;101(10):2209-17.  
7- Alatise OI, Owojuyigbe AM, Yakubu MA, Agbakwuru 
AE, Faponle AF. Propofol versus traditional sedative 
methods for colonoscopy in a low-resource setting. Niger 
Postgrad Med J. 2015;22(3):151-7. 
8- Ingrande J, Brodsky JB, Lemmens HJ. Lean body 
weight scalar for the anesthetic induction dose of 
propofol in morbidly obese subjects. Anesth Analg. 
2011;113(1):57-62. 
9- Wang D, Chen C, Chen J, Xu Y, Wang L, Zhu Z, et al. The 
use of propofol as a sedative agent in gastrointestinal 
endoscopy: A meta-analysis. PLoS ONE. 
2013;8(1):e53311. 
10- Naderi B, Haghighi M, Sedighinezhad A, 
Mohammadzade A, Mirzazade B. The comparison of 
different propofol dose for anesthesia induction based 
on BIS monitoring. J Guilan Univ Med Sci. 
2008;17(65):88-93. [Persian] 
11- Shahbazi Sh, Haghighat A, Zand F. Bispecteral index 
and the amount of drugs needed in coronary artery 
bypass grafting under propofol: Remifentanil anesthesia 
method. J Iran Soc Anesthesiol Intensiv Care. 
2005;4(52):5-14. [Persian] 
12- Muralidhar K, Banakal S, Murthy K, Garg R, Rani GR, 
Dinesh R. Bispectral index-guided anaesthesia for off-
pump coronary artery bypass grafting. Ann Card 
Anaesth. 2008;11(2):105-10. 
13- Aprea F, Martin-Jurado O, Jenni S, Mosing M. 
Bispectral index analysis during cardiac arrest and 
cardiopulmonary resuscitation in a propofol-
anesthetized calf. J Vet Emerg Crit Care (San Antonio). 
2014;24(2):221-5. 
14- Jabalameli M, Hazegh N, Gholami S. The effects of 
hyperbaric or isobaric bupivacaine on bispectral index in 
spinal anesthesia for cesarean section. J Res Med Sci. 
2012;17(2):176-81. 
15- Punjasawadwong Y, Phongchiewboon A, 
Bunchungmongkol N. Bispectral index for improving 
anaesthetic delivery and postoperative recovery. 
Cochrane Database Syst Rev. 2017;(4): CD003843.  
16- Klopman MA, Sebel PS. Cost-effectiveness of 
bispectral index monitoring. Curr Opin Anaesthesiol. 
2011;24(2):177-81. 
17- Saber Moghadam M, Nikdelan AA, Alavinia SM. The 
incidence of abnormal movements and its associated 
factors during the induction of anesthesia with propofol . 
J North Khorasan Univ Med Sci. 2012;3(4):119-24. 
[Persian] 
18- Levy RJ. Clinical effects and lethal and forensic 
aspects of propofol. J Forensic Sci. 2011;56(0 1):S142-7. 
19- Symington L, Thakore S. A review of the use of 
propofol for procedural sedation in the emergency 
department. Emerg Med J. 2006;23(2):89-93.  
20- Giese JL, Stockham RJ, Stanley TH, Pace NL, Nelissen 
RH. Etomidate versus thiopental for induction of 
anesthesia. Anesth Analg. 1985;64(9):871-6. 
21- Seyed Hejazi M, Eydi M, Ghojazadeh M, Nejati A, 
Ghabili K, Golzari SEJ, et al. Propofol for laryngeal mask 
airway insertion in children: Effect of two different 
doses. Saudi J Anaesth. 2013;7(3):266-9. 
22- Zahoor A, Ahmed N. The effects of duration of 
injection on hemodynamics. Middle East J Anaesthesiol. 
2010;20(6):846-50. 
23- Heck M, Kumle B, Boldt J, Lang J, Lehmann A, Saggau 
W. Electroencephalogram bispectral index predicts 
hemodynamic and arousal reactions during induction of 
anesthesia in patients undergoing cardiac surgery. J 
Cardiothorac Vasc Anesth. 2000;14(6):693-7. 
